Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
7.77
+0.09 (1.17%)
Aug 18, 2026, 2:01 PM EDT - Market open
CPIX Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 40.18 | 40.4 | 36.54 | 37.51 | 40.68 | 35.05 |
Other Revenue | 4.13 | 4.13 | 1.33 | 2.04 | 1.33 | 0.94 |
| 44.3 | 44.52 | 37.87 | 39.55 | 42.01 | 35.99 | |
Revenue Growth | 120.76% | 17.57% | -4.26% | -5.85% | 16.75% | -3.89% |
Cost of Revenue | 6.67 | 6.67 | 6.59 | 6.07 | 9.12 | 8.81 |
Gross Profit | 37.64 | 37.85 | 31.28 | 33.49 | 32.89 | 27.17 |
Selling, General & Admin | 31.06 | 31.05 | 28.15 | 29.1 | 26.84 | 24.8 |
Research & Development | 5.58 | 5.57 | 4.82 | 5.83 | 6.69 | 5.68 |
Amortization of Goodwill & Intangibles | 4.04 | 4.03 | 4.75 | 4.76 | 5.07 | 4.37 |
Operating Expenses | 40.68 | 40.65 | 37.71 | 39.7 | 38.6 | 34.85 |
Operating Income | -3.04 | -2.79 | -6.43 | -6.21 | -5.7 | -7.68 |
Interest Expense | -0.49 | -0.5 | -0.61 | -0.67 | -0.59 | -0.1 |
Interest & Investment Income | 0.36 | 0.48 | 0.33 | 0.29 | 0.1 | 0.03 |
Earnings From Equity Investments | -0.01 | -0.01 | - | - | - | - |
Other Non Operating Income (Expenses) | - | - | - | 3.3 | - | - |
EBT Excluding Unusual Items | -3.19 | -2.82 | -6.7 | -3.29 | -6.19 | -7.75 |
Asset Writedown | - | - | - | -3.34 | - | - |
Other Unusual Items | - | - | - | - | - | 2.19 |
Pretax Income | -3.19 | -2.82 | -6.47 | -6.28 | -5.58 | -5.56 |
Income Tax Expense | 0.04 | 0.04 | -0.02 | 0.05 | 0.07 | 0.03 |
Earnings From Continuing Operations | -3.22 | -2.86 | -6.44 | -6.33 | -5.65 | -5.6 |
Earnings From Discontinued Operations | -7.72 | - | - | - | - | 1.99 |
Net Income to Company | -10.94 | -2.86 | -6.44 | -6.33 | -5.65 | -3.6 |
Minority Interest in Earnings | 0.02 | 0.03 | -0.04 | 0.05 | 0.08 | 0.1 |
Net Income | -10.92 | -2.84 | -6.48 | -6.28 | -5.57 | -3.51 |
Net Income to Common | -10.92 | -2.84 | -6.48 | -6.28 | -5.57 | -3.51 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 15 | 15 | 14 | 14 | 15 | 15 |
Shares Outstanding (Diluted) | 15 | 15 | 14 | 14 | 15 | 15 |
Shares Change | 2.64% | 5.65% | -1.67% | -1.82% | -2.29% | -1.70% |
EPS (Basic) | -0.73 | -0.19 | -0.46 | -0.44 | -0.38 | -0.24 |
EPS (Diluted) | -0.74 | -0.19 | -0.46 | -0.44 | -0.38 | -0.24 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 0.68 | 4.83 | -0.68 | 5.81 | 8.35 | 6.24 |
Free Cash Flow Per Share | 0.05 | 0.33 | -0.05 | 0.41 | 0.57 | 0.42 |
Gross Margin | 84.95% | 85.02% | 82.61% | 84.66% | 78.30% | 75.51% |
Operating Margin | -6.87% | -6.27% | -16.99% | -15.70% | -13.58% | -21.34% |
Profit Margin | -24.64% | -6.37% | -17.11% | -15.88% | -13.26% | -9.75% |
Free Cash Flow Margin | 1.54% | 10.86% | -1.79% | 14.70% | 19.88% | 17.34% |
EBITDA | 1.1 | 1.35 | -1.53 | -1.27 | -0.38 | -3.07 |
EBITDA Margin | 2.48% | 3.04% | -4.04% | -3.22% | -0.90% | -8.53% |
D&A For EBITDA | 4.14 | 4.15 | 4.9 | 4.94 | 5.33 | 4.61 |
EBIT | -3.04 | -2.79 | -6.43 | -6.21 | -5.7 | -7.68 |
EBIT Margin | -6.87% | -6.27% | -16.99% | -15.70% | -13.58% | -21.34% |
Revenue as Reported | 44.52 | 44.52 | 37.87 | 39.55 | 42.01 | 35.99 |
Advertising Expenses | - | 2.73 | 2.99 | 2.9 | 2.93 | 1.93 |